Nicholas A Marston

TL;DR: In this paper, randomized trials of therapies that primarily lowered triglycerides have not consistently shown reductions in cardiovascular events, and they performed a systematic review and trial-based evaluation of the effectiveness of these therapies.

TL;DR: Patients with high genetic risk, regardless of clinical risk, had a high event rate and derived the greatest relative and absolute benefit from evolocumab, which mitigated this risk.

TL;DR: In this article, a prospective cohort analysis included individuals from the population-based UK Biobank and from two large international clinical trials, FOURIER and IMPROVE-IT, to determine whether common measures of cholesterol concentration, TG concentration, or their ratio are associated with cardiovascular risk beyond the number of apolipoprotein B (apoB)-containing lipoproteins.

TL;DR: In this article , a cross-ancestry GWAS meta-analyses of 110,182 patients who have had a stroke (five ancestries, 33% non-European) and 1,503,898 control individuals, identify association signals for stroke and its subtypes at 89 (61 new) independent loci: 60 in primary inverse-variance-weighted analyses and 29 in secondary meta-regression and multitrait analyses.

TL;DR: This work sets out to determine the effect of PCSK9 on cholesterol levels and risk of venous thromboembolism in patients with a history of VTE.